Oragenics Announces 1-for-30 Reverse Stock Split to Enhance Market Profile
Oragenics announces a 1-for-30 reverse stock split to boost share price and appeal to investors. CEO Janet Huffman aims to enhance the company's capital markets profile while advancing treatments for brain-related health conditions.
This news matters as the reverse stock split by Oragenics aims to increase the company's share price and attract long-term investors. It reflects the company's commitment to advancing treatments for brain-related health conditions and improving its capital markets profile.
